Merely a few conditions now being pursued for secondary prevention or treatment with #GLP-1/GIP/glucagon drugs like #Ozempic or #Zepbound
Alzheimer disease
Parkinson disease
Stroke
Heart failure
CKD
MASLD/MASH
Type 2 diabetes
Sleep apnea
Psoriasis
Osteoarthritis
Substance use disorder
ALS
And more 🤗
We may be watching the emergence of an entirely new class of systems-level disease modifiers, not just “weight loss drugs.”







